Literature DB >> 16299383

Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas.

Frédérique Souazé1, Véronique Viardot-Foucault, Nicolas Roullet, Mireille Toy-Miou-Leong, Anne Gompel, Erik Bruyneel, Eva Comperat, Maree C Faux, Marc Mareel, William Rostène, Jean-François Fléjou, Christian Gespach, Patricia Forgez.   

Abstract

Alterations in the Wnt/APC (adenomatous polyposis coli) signalling pathway, resulting in beta-catenin/T cell factor (Tcf)-dependent transcriptional gene activation, are frequently detected in familial and sporadic colon cancers. The neuropeptide neurotensin (NT) is widely distributed in the gastrointestinal tract. Its proliferative and survival effects are mediated by a G-protein coupled receptor, the NT1 receptor. NT1 receptor is not expressed in normal colon epithelial cells, but is over expressed in a number of cancer cells and tissues suggesting a link to the outgrowth of human colon cancer. Our results demonstrate that the upregulation of NT1 receptor occurring in colon cancer is the result of Wnt/APC signalling pathway activation. We first established the functionality of the Tcf response element within the NT1 receptor promoter. Consequently, we observed the activation of NT1 receptor gene by agents causing beta-catenin cytosolic accumulation, as well as a strong decline of endogenous receptor when wt-APC was restored. At the cellular level, the re-establishment of wt-APC phenotype resulted in the impaired functionality of NT1 receptor, like the breakdown in NT-induced intracellular calcium mobilization and the loss of NT pro-invasive effect. We corroborated the Wnt/APC signalling pathway on the NT1 receptor promoter activation with human colon carcinogenesis, and showed that NT1 receptor gene activation was perfectly correlated with nuclear or cytoplasmic beta-catenin localization while NT1 receptor was absent when beta-catenin was localized at the cell-cell junction in early adenomas of patients with familial adenomatous polyposis, hereditary non-polyposis colorectal cancer and loss of heterozygosity tumours. In this report we establish a novel link in vitro between the Tcf/beta-catenin pathway and NT1 receptor promoter activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299383     DOI: 10.1093/carcin/bgi269

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  29 in total

1.  The neurotensin receptor-1 promotes tumor development in a sporadic but not an inflammation-associated mouse model of colon cancer.

Authors:  James M Bugni; Leina Al- Rabadi; Kevin Jubbal; Iordanis Karagiannides; Gregory Lawson; Charalabos Pothoulakis
Journal:  Int J Cancer       Date:  2011-11-17       Impact factor: 7.396

Review 2.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

3.  Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome.

Authors:  Mikaël Agopiantz; Patricia Forgez; Jean-Matthieu Casse; Stéphanie Lacomme; Claire Charra-Brunaud; Isabelle Clerc-Urmès; Olivier Morel; Céline Bonnet; Jean-Louis Guéant; Jean-Michel Vignaud; Anne Gompel; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2017-08-24       Impact factor: 4.064

4.  Neurotensin receptor 1 overexpression in inflammatory bowel diseases and colitis-associated neoplasia.

Authors:  Xianyong Gui; Shuhong Liu; Yuchu Yan; Zuhua Gao
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

5.  Exploratory Analysis of Plasma Neurotensin as a Novel Biomarker for Early Detection of Colorectal Polyp and Cancer.

Authors:  Shengyang Qiu; Stella Nikolaou; Francesca Fiorentino; Shahnawaz Rasheed; Ara Darzi; David Cunningham; Paris Tekkis; Christos Kontovounisios
Journal:  Horm Cancer       Date:  2019-05-15       Impact factor: 3.869

6.  Neurotensin stimulates expression of early growth response gene-1 and EGF receptor through MAP kinase activation in human colonic epithelial cells.

Authors:  Dezheng Zhao; Yanai Zhan; Huiyan Zeng; Hon Wai Koon; Mary P Moyer; Charalabos Pothoulakis
Journal:  Int J Cancer       Date:  2007-04-15       Impact factor: 7.396

7.  Neurotensin, a novel target of Wnt/β-catenin pathway, promotes growth of neuroendocrine tumor cells.

Authors:  Ji Tae Kim; Chunming Liu; Yekaterina Y Zaytseva; Heidi L Weiss; Courtney M Townsend; B Mark Evers
Journal:  Int J Cancer       Date:  2014-08-14       Impact factor: 7.396

8.  SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.

Authors:  Terry W Moody; Daniel C Chan; Samuel A Mantey; Paola Moreno; Robert T Jensen
Journal:  Life Sci       Date:  2014-02-02       Impact factor: 5.037

9.  The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer.

Authors:  George Sgourakis; Aggeliki Papapanagiotou; Christos Kontovounisios; Michalis V Karamouzis; Georgia Dedemadi; Constantine Goumas; Constantine Karaliotas; Athanasios G Papavassiliou
Journal:  Tumour Biol       Date:  2014-03-14

10.  Platelet-derived growth factor-BB restores HIV Tat -mediated impairment of neurogenesis: role of GSK-3β/β-catenin.

Authors:  Jie Chao; Lu Yang; Honghong Yao; Shilpa Buch
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.